Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement.

Analytical chemistry - 2 Apr 2024

D'Ippolito Robert A, Rabara Dana, Blanco Maria Abreu, Alberico Emily, Drew Matthew R, Ramakrishnan Nitya, Sontan Dara, Widmeyer Stephanie R T, Scheidemantle Grace M, Messing Simon, Turner David, Arkin Michelle, Maciag Anna E, Stephen Andrew G, Esposito Dominic, McCormick Frank, Nissley Dwight V, DeHart Caroline J

Abstract excerpt

Development of new targeted inhibitors for oncogenic KRAS mutants may benefit from insight into how a given mutation influences the accessibility of protein residues and how compounds interact with mutant or wild-type KRAS proteins. Targeted proteomic analysis, a key validation step in the KRAS inhibitor development process, typically involves both intact mass- and peptide-based methods to confirm compound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding Sites
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 38498381
DOI: 10.1021/acs.analchem.3c05626
PMCID: PMC10993199

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement.PMID 38498381Read ↗

Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.Semantic proximity Read ↗

Accelerating the Validation of Endogenous On-Target Engagement and In Cellulo Kinetic Assessment for Covalent Inhibitors of KRASG12C in Early Drug Discovery.Semantic proximity Read ↗

MALDI-TOF Mass Spectrometry-Based Assay for Measuring Covalent Target Engagement of KRAS G12C Inhibitors.Semantic proximity Read ↗

Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.Semantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.Semantic proximity Read ↗

Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry.Semantic proximity Read ↗

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.Semantic proximity Read ↗

Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded StatesSemantic proximity Read ↗

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.Semantic proximity Read ↗

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS2.Semantic proximity Read ↗

Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.